Skip to main content
Premium Trial:

Request an Annual Quote

Istvan Merchenthaler, David King, Janice DiPietro, Leslie Brown, and James Greenwood

Premium

Istvan Merchenthaler has been appointed chief medical officer at Phylogeny, the company said last week.

Merchenthaler will oversee functional genomics studies for Phylogeny’s pharmaceutical and biotech clients, with an emphasis on understanding gene expression patterns in the central nervous system, the company said.

Prior to joining Phylogeny, Merchenthaler was employed by Wyeth Research, where he served as a distinguished research scientist and director of functional morphology for the company’s Women’s Health Research Institute for 10 years. He has also held visiting scientist positions at the National Institutes of Health. He holds an MD from the University Medical School in Pecs, Hungary, as well as a PhD in medicine and neuroendocrinology.


Guava Technologies has named David King as vice president of product development, the company said yesterday.

King joins Guava from Iolon, a privately-held manufacturer of tunable optical components, where he was head of new product development and product integration. Prior to this, he was principal engineer at Agilent Technologies. He has also been employed by Hewlett Packard.

King received his MS and PhD in applied physics from Stanford University.


Janice DiPietro has been appointed chief financial officer at MultiCell Technologies. DiPietro is currently a managing partner of Tatum Partners and is responsible for the firm’s practice in Boston and the New England region. Prior to joining Tatum Partners, DiPietro was executive vice president and chief financial officer of NewDeal.

DiPietro graduated with honors from Bentley College and holds an MBA and doctoral in accounting from Boston University.


Pharmacopeia Drug Discovery has named Leslie Brown as president and chief executive officer, the company announced last week.

Most recently, Brown served as chief operating officer at Iconix Pharmaceuticals. He has also been the chief operating officer at functional genomics company GeneTrace. From 1990 to 2000, Brown held a number of senior positions at Berlex/Schering AG including corporate vice president of Berlex Labs and president of Schering Berlin Venture.

Brown received his PhD from the University of Michigan, and was an NIH postdoctoral fellow at Harvard with Nobel laureate professor R.B. Woodward.


Congressman James Greenwood (R) was named the next president of the Biotechnology Industry Organization last week.

Greenwood has represented the Eighth District of Pennsylvania in the US House of Representatives since 1993, and serves on the Energy and Commerce, and Education and the Workforce Committees. He previously served in the Pennsylvania House and Senate.

Since 2001, Greenwood has served as chairman of the Energy and Commerce Subcommittee on Oversight and Investigations. He will be replacing Carl Feldbaum, who has headed BIO since its establishment in July 1993, and announced plans for his retirement in February.

 

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.